Page 89 - Škrgat, Sabina, ed. 2022. Severe Asthma - Basic and Clinical Views. Koper: University of Primorska Press. Severe Asthma Forum, 1
P. 89
Foundation for Medical Education and 36. Bommarito L, Migliore E, Bugiani M, 89
Research; c1995-2022 [cited 2022 Mar et al. Exhaled nitric oxide in a popu-
12]. Available from: https://www.may- lation sample of adults. Respiration. biomarkers in severe asthma
ocliniclabs.com/test-catalog/Clini- 2008;75(4):386-92.
cal+and+Interpretive/8159.
29. Jayaram L, Pizzichini MM, Cook RJ, 37. Dweik RA, Boggs PB, Erzurum SC,
et al. Determining asthma treatment by et al. An official ATS clinical practice
monitoring sputum cell counts: effect guideline: Interpretation of exhaled ni-
on exacerbations. Eur Respir J. 2006 tric oxide levels (FENO) for clinical ap-
Mar;27(3):483-94. plications. Am J Respir Crit Care Med.
30. Schleich FN, Manise M, Sele J, et al. 2011 Sep 1;184(5):602-15.
Distribution of sputum cellular pheno-
type in a large asthma cohort: predict- 38. Price DB, Bosnic-Anticevich S, Pavord
ing factors for eosinophilic vs neutro- ID, et al. Association of elevated frac-
philic inflammation. BMC Pulm Med. tional exhaled nitric oxide concentra-
2013 Feb 26;13:11. doi: 10.1186/1471- tion and blood eosinophil count with se-
2466-13-11. vere asthma exacerbations. Clin Transl
31. Zaihra T, Walsh CJ, Ahmed S, et al. Allergy. 2019 Aug 21;9:41. doi: 10.1186/
Phenotyping of difficult asthma using s13601-019-0282-7.
longitudinal physiological and biomark-
er measurements reveals significant dif- 39. Brooks EA, Massanari M, Hanania NA,
ferences in stability between clusters. et al. Cost-effectiveness of fractional ex-
BMC Pulm Med. 2016 May 10;16(1):74. haled nitric oxide (FeNO) measurement
doi: 10.1186/s12890-016-0232-2. in predicting response to omalizumab
32. Ntontsi P, Loukides S, Bakakos P, et al. in asthma. Clinicoecon Outcomes Res.
Clinical, functional and inflammato- 2019 Apr 17;11:301-7.
ry characteristics in patients with pauci-
granulocytic stable asthma: Compari-
son with different sputum phenotypes.
Allergy. 2017 Nov;72(11):1761-7.
33. Korevaar DA, Westerhof GA, Wang J,
et al. Diagnostic accuracy of minimally
invasive markers for detection of airway
eosinophilia in asthma: a systematic re-
view and meta-analysis. Lancet Respir
Med. 2015 Apr;3(4):290-300.
34. Agache I, Akdis C, Jutel M, et al. Un-
tangling asthma phenotypes and endo-
types. Allergy. 2012 Jul;67(7):835-46.
35. Neelamegan R, Saka V, Tamilarasu K,
et al. Clinical Utility of Fractional ex-
haled Nitric Oxide (FeNO) as a Bio-
marker to Predict Severity of Disease
and Response to Inhaled Corticosteroid
(ICS) in Asthma Patients. J Clin Diagn
Res. 2016 Dec;10(12):FC01-FC6. doi:
10.7860/JCDR/2016/20656.8950.
Research; c1995-2022 [cited 2022 Mar et al. Exhaled nitric oxide in a popu-
12]. Available from: https://www.may- lation sample of adults. Respiration. biomarkers in severe asthma
ocliniclabs.com/test-catalog/Clini- 2008;75(4):386-92.
cal+and+Interpretive/8159.
29. Jayaram L, Pizzichini MM, Cook RJ, 37. Dweik RA, Boggs PB, Erzurum SC,
et al. Determining asthma treatment by et al. An official ATS clinical practice
monitoring sputum cell counts: effect guideline: Interpretation of exhaled ni-
on exacerbations. Eur Respir J. 2006 tric oxide levels (FENO) for clinical ap-
Mar;27(3):483-94. plications. Am J Respir Crit Care Med.
30. Schleich FN, Manise M, Sele J, et al. 2011 Sep 1;184(5):602-15.
Distribution of sputum cellular pheno-
type in a large asthma cohort: predict- 38. Price DB, Bosnic-Anticevich S, Pavord
ing factors for eosinophilic vs neutro- ID, et al. Association of elevated frac-
philic inflammation. BMC Pulm Med. tional exhaled nitric oxide concentra-
2013 Feb 26;13:11. doi: 10.1186/1471- tion and blood eosinophil count with se-
2466-13-11. vere asthma exacerbations. Clin Transl
31. Zaihra T, Walsh CJ, Ahmed S, et al. Allergy. 2019 Aug 21;9:41. doi: 10.1186/
Phenotyping of difficult asthma using s13601-019-0282-7.
longitudinal physiological and biomark-
er measurements reveals significant dif- 39. Brooks EA, Massanari M, Hanania NA,
ferences in stability between clusters. et al. Cost-effectiveness of fractional ex-
BMC Pulm Med. 2016 May 10;16(1):74. haled nitric oxide (FeNO) measurement
doi: 10.1186/s12890-016-0232-2. in predicting response to omalizumab
32. Ntontsi P, Loukides S, Bakakos P, et al. in asthma. Clinicoecon Outcomes Res.
Clinical, functional and inflammato- 2019 Apr 17;11:301-7.
ry characteristics in patients with pauci-
granulocytic stable asthma: Compari-
son with different sputum phenotypes.
Allergy. 2017 Nov;72(11):1761-7.
33. Korevaar DA, Westerhof GA, Wang J,
et al. Diagnostic accuracy of minimally
invasive markers for detection of airway
eosinophilia in asthma: a systematic re-
view and meta-analysis. Lancet Respir
Med. 2015 Apr;3(4):290-300.
34. Agache I, Akdis C, Jutel M, et al. Un-
tangling asthma phenotypes and endo-
types. Allergy. 2012 Jul;67(7):835-46.
35. Neelamegan R, Saka V, Tamilarasu K,
et al. Clinical Utility of Fractional ex-
haled Nitric Oxide (FeNO) as a Bio-
marker to Predict Severity of Disease
and Response to Inhaled Corticosteroid
(ICS) in Asthma Patients. J Clin Diagn
Res. 2016 Dec;10(12):FC01-FC6. doi:
10.7860/JCDR/2016/20656.8950.
